This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Krystexxa

Horizon Pharma plc

Drug Names(s): pegloticase, PEG-uricase, Puricase

Description: Puricase is a genetically engineered polyethylene glycol (PEG) conjugate of uricase, an enzyme that converts uric acid into a highly soluble and more easily excreted product.

Deal Structure: Duke University, Mountain View and Savient
The production of the active pharmaceutical ingredient (API) is based on a recombinant microorganism, the subject of an issued patent owned by Duke University, and licensed exclusively to Savient, as well as published patent applications owned directly by the company. The manufacturing processes used in the production of the API consist in most part of standard biotechnological techniques, except for the PEGylation step. The manufacturing process steps are covered by published patent applications owned directly by Savient and by an issued patent exclusively licensed to the company by Mountain View Pharmaceuticals.

The license agreement requires Savient to pay to Mountain View and Duke quarterly royalty payments within sixty days after the end of each quarter based on net sales Savient makes in that quarter. The royalty rate for a particular quarter ranges between 8% and 12% of net sales based on the amount of cumulative net...See full deal structure in Biomedtracker

Partners: Mountain View Pharmaceuticals, Inc.


Krystexxa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug